{"entity":{"id":"nct07602855","kind":"trial","name":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)","aka":[],"tldr":"A phase 1/2 trial of ivonescimab in lung cancer, run by GlaxoSmithKline, now recruiting.","summary":"A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103) is a phase 1/2, interventional study registered as NCT07602855 by GlaxoSmithKline, with a registry enrolment figure of 184 participants, started 2026-09-09 and due to reach its primary completion in 2029-06-22. Interventions recorded: Risvutatug rezetecan; Ivonescimab. Conditions listed: Neoplasms, Lung. Primary outcome: Phase 1 and Phase 2 Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) and Adverse events of special interest (AESIs); Phase 1 and Phase 2: Number of participants with AEs leading to dose modifications including study intervention discontinuation; Phase 2: Number of part. Lung eligibility wording from the registry: \"ES-SCLC\". Sites: Japan, United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07602855","url":"https://clinicaltrials.gov/study/NCT07602855"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["antiangiogenic","bispecific-antibody","checkpoint-inhibitor"],"targets":[],"drugs":["ivonescimab"],"companies":["gsk"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07602855","phase":"1/2","setting":"A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors","sponsor":"GlaxoSmithKline","enrolled":184,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07602855/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"}],"company":[{"id":"gsk","kind":"company","name":"GSK","route":"/companies/gsk/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}